A phase II study of Pro-NETU in patients receiving highly emetogenic chemotherapy (HEC)

Trial Profile

A phase II study of Pro-NETU in patients receiving highly emetogenic chemotherapy (HEC)

Recruiting
Phase of Trial: Phase II

Latest Information Update: 22 Sep 2016

At a glance

  • Drugs Fosnetupitant (Primary)
  • Indications Chemotherapy-induced nausea and vomiting
  • Focus Therapeutic Use
  • Sponsors Taiho Pharmaceutical
  • Most Recent Events

    • 06 Sep 2016 Status changed from not yet recruiting to recruiting.
    • 25 Aug 2016 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top